Q2 2022 13F Holders as of 6/30/2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
207M
-
Number of holders
-
124
-
Total 13F shares, excl. options
-
55.2M
-
Shares change
-
+3.86M
-
Total reported value, excl. options
-
$351M
-
Value change
-
+$25.2M
-
Put/Call ratio
-
0.25
-
Number of buys
-
63
-
Number of sells
-
-52
-
Price
-
$6.36
Significant Holders of Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) as of Q2 2022
151 filings reported holding ESPR - Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q2 2022.
Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) has 124 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 55.2M shares
of 207M outstanding shares and own 26.62% of the company stock.
Largest 10 shareholders include WASATCH ADVISORS INC (7.55M shares), Deep Track Capital, LP (6M shares), Meditor Group Ltd (4.47M shares), VANGUARD GROUP INC (4.3M shares), BlackRock Inc. (4.29M shares), Bellevue Group AG (4.24M shares), MILLENNIUM MANAGEMENT LLC (2.71M shares), Ikarian Capital, LLC (2.05M shares), PLATINUM INVESTMENT MANAGEMENT LTD (1.62M shares), and Paradigm Biocapital Advisors LP (1.41M shares).
This table shows the top 124 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.